Praxis Precision Medicines closed at $284.79 on Nov 4, up 1.53%, 26.3% below its 52-week closing high. Volume of 372.9K shares was 0.74× its 20-day average (below normal).
Split-adjusted performance: +1.7% over one month, -15.8% over six months, +56.5% over one year.
Short interest was 3.9M shares at the Oct 15 settlement, down 6.4% from the prior report (14.1% of float, 7.4 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| PRAXPraxis Precision Medicines | $284.79 | +1.53% | −15.8% | — | — | — | $7.95B | |
| ALKSAlkermes | $45.89 | +0.44% | +29.9% | +21.8% | 3.4% | — | $7.70B | Compare |
| RYTMRhythm Pharmaceuticals | $110.68 | +28.04% | +14.6% | +46.9% | −70.7% | — | $7.62B | Compare |
| KNSAKiniksa Pharmaceuticals International | $96.12 | +3.03% | +65.1% | +58.1% | 16.6% | 68.9 | $7.55B | Compare |
| CORTCorcept Therapeutics | $79.22 | −3.31% | +51.9% | +31.7% | 16.8% | 157.2 | $8.56B | Compare |
| ARWRArrowhead Research | $61.65 | +3.56% | −22.1% | +171.0% | −258.2% | — | $8.71B | Compare |
| AXSMAxsome Therapeutics | $137.00 | −1.87% | −38.5% | +51.9% | −5.0% | — | $7.18B | Compare |
| CYTKCytokinetics | $63.60 | +2.07% | −15.0% | −57.1% | −694.4% | — | $8.84B | Compare |
| AMRXAmneal Pharmaceuticals | $19.95 | −1.29% | +46.5% | +9.9% | 7.2% | 44.2 | $6.95B | Compare |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
